Eosinophilic Gastroenteritis Market is Projected to Advance During the Forecast Period (2032) | Key Companies – AstraZeneca, Allakos, and Others

Eosinophilic Gastroenteritis Market is Projected to Advance During the Forecast Period (2032) | Key Companies - AstraZeneca, Allakos, and Others

“Delveinsight Business Research LLP”
DelveInsight’s “Eosinophilic Gastroenteritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Eosinophilic Gastroenteritis Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Eosinophilic Gastroenteritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Get the Sample Copy of the Report, at: Eosinophilic Gastroenteritis Therapeutics Market Analysis


Eosinophilic Gastroenteritis Market

Eosinophilic Gastroenteritis: An Overview

Eosinophilic Gastroenteritis (EGE) is a rare digestive disease characterized by the triad of eosinophilic infiltration of segments of the gastrointestinal tract, abnormalities of gastrointestinal function (varying from dyspepsia and obstruction to diarrhea and ascites), and exclusion of other diseases with peripheral eosinophilia.

Approved disease-specific treatment for EGE patients is not currently available, although several new molecules are under investigation. Treatment with several medications like corticosteroids and PPI inhibitors can slow the progress of the disease and help manage symptoms.

Eosinophilic Gastroenteritis Market Key Facts

  • In 2020, among the 7MM, the Eosinophilic Gastroenteritis prevalent cases were highest in the US, with 30,133 cases, and the lowest in Spain with 2,695 cases.

  • Among EU5 countries, Germany had the highest number of prevalent cases of eosinophilic gastroenteritis (4,329 cases) in 2020.

  • According to DelveInsight’s analysis, there are slightly more cases in males than females in the US. However, like eosinophilic esophagitis (EoE), there is no male predominance in EGE.

  • In the United States, EGE is considered very rare, with an estimated prevalence of 8.2/100,000. 

  • In Japan, eosinophilic gastrointestinal disorder (EGID) is an intractable disease designated by the Ministry of Health, Labor, and Welfare from 2015. According to a report by the research group, there are more than 5,000 patients in Japan. As per their annual report, 700 incident patients are being treated for EGIDs in Japan.

Eosinophilic Gastroenteritis (EGE) Market

As per DelveInsight, the Eosinophilic Gastroenteritis (EGE) Market size in the 7MM was found to be USD 109.3 million in 2020, which is expected to increase owing to the growing awareness, improved management, and better outcomes.

DelveInsight’s analysts estimate that the market is expected to show positive growth, mainly attributed to increased prevalence and the anticipated launch of novel therapies during the forecast period.

Eosinophilic Gastroenteritis Market Outlook

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Eosinophilic Gastroenteritis market size and share by analyzing the impact of current and emerging therapies on the market. It also provides a detailed assessment of the unmet needs, market drivers barriers, and emerging technologies.

The report gives a thorough detail of the Eosinophilic Gastroenteritis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Eosinophilic Gastroenteritis (EGE) Market Drivers

  • Increasing prevalence of eosinophilic GI disorders

  • Improvements in comprehensive diagnostic criteria

  • A better understanding of disease pathogenesis

Eosinophilic Gastroenteritis Epidemiology

The epidemiology section covers insights about the historical and current Eosinophilic Gastroenteritis patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Eosinophilic Gastroenteritis (EGE) Epidemiology Segmentation

  • Total Prevalent Cases of Eosinophilic Gastroenteritis

  • Gender-specific Cases of Eosinophilic Gastroenteritis

  • Age-specific Cases of Eosinophilic Gastroenteritis

Eosinophilic Gastroenteritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Eosinophilic Gastroenteritis market or expected to get launched in the market during the study period. The analysis covers Eosinophilic Gastroenteritis market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Eosinophilic Gastroenteritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Eosinophilic Gastroenteritis Therapeutics Market

The Eosinophilic Gastroenteritis (EGE) Market has a promising outlook with some of the best potential emerging therapies in the pipeline expected to launch in the coming years. 

Some of the key companies in the Eosinophilic Gastroenteritis (EGE) Market. 

  • AstraZeneca

  • Allakos

And others

Eosinophilic Gastroenteritis (EGE) Therapies covered in the report include:

  • Lirentelimab

  • Benralizumab

  • Esomeprazole + Budesonide

And Others

Get the Sample Copy of the Report, at:  https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market

Table of Content

1. Key Insights

2. Executive Summary 

3. Eosinophilic Gastroenteritis Competitive Intelligence Analysis

4. Eosinophilic Gastroenteritis Market Overview at a Glance

5. Eosinophilic Gastroenteritis Disease Background and Overview

6. Eosinophilic Gastroenteritis Patient Journey

7. Eosinophilic Gastroenteritis Epidemiology and Patient Population

8. Eosinophilic Gastroenteritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Eosinophilic Gastroenteritis Unmet Needs

10. Key Endpoints of Eosinophilic Gastroenteritis Treatment

11. Eosinophilic Gastroenteritis Marketed Products

12. Eosinophilic Gastroenteritis Emerging Therapies

13. Eosinophilic Gastroenteritis Seven Major Market Analysis

14. Attribute Analysis

15. Eosinophilic Gastroenteritis Market Outlook (7 major markets)

16. Eosinophilic Gastroenteritis Access and Reimbursement Overview

17. KOL Views on the Eosinophilic Gastroenteritis Market.

18. Eosinophilic Gastroenteritis Market Drivers

19. Eosinophilic Gastroenteritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/